A citation-based method for searching scientific literature

Devinder S Dhindsa, Anurag Mehta, Pratik B Sandesara, Aneesha Thobani, Stephen Brandt, Laurence S Sperling. Curr Cardiol Rep 2019
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity






Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Raffaella Gentilella, Valeria Pechtner, Antonella Corcos, Agostino Consoli. Diabetes Metab Res Rev 2019
66
50


SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018).
Jyotsana Pandey, Akhilesh K Tamrakar. Expert Opin Ther Pat 2019
7
50

Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
Matteo Monami, Besmir Nreu, Alessia Scatena, Barbara Cresci, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci. Diabetes Obes Metab 2017
69
50


Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.
John D Bucheit, Lauren G Pamulapati, Nicole Carter, Kevin Malloy, Dave L Dixon, Evan M Sisson. Diabetes Technol Ther 2020
22
50

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Richard Pratley, Aslam Amod, Søren Tetens Hoff, Takashi Kadowaki, Ildiko Lingvay, Michael Nauck, Karen Boje Pedersen, Trine Saugstrup, Juris J Meier. Lancet 2019
114
50

GLP-1 receptor agonists: a review of head-to-head clinical studies.
Jennifer M Trujillo, Wesley Nuffer, Samuel L Ellis. Ther Adv Endocrinol Metab 2015
168
50


Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.
Bernard Zinman, Vanita R Aroda, John B Buse, Bertrand Cariou, Stewart B Harris, Søren Tetens Hoff, Karen Boje Pedersen, Mads Jeppe Tarp-Johansen, Eiichi Araki. Diabetes Care 2019
45
50

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Melanie Davies, Thomas R Pieber, Marie-Louise Hartoft-Nielsen, Oluf K H Hansen, Serge Jabbour, Julio Rosenstock. JAMA 2017
153
50

Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review.
Alexandra M Bodnaruc, Denis Prud'homme, Rosanne Blanchet, Isabelle Giroux. Nutr Metab (Lond) 2016
37
50

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund, Jan W Eriksson, Simon Heller, Ole Holm Hels, Richard Pratley, Thozhukat Sathyapalan, Cyrus Desouza. Lancet Diabetes Endocrinol 2019
62
50

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen. Lancet Diabetes Endocrinol 2018
183
50

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Thomas R Pieber, Bruce Bode, Ann Mertens, Young Min Cho, Erik Christiansen, Christin L Hertz, Signe O R Wallenstein, John B Buse. Lancet Diabetes Endocrinol 2019
64
50

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yuichiro Yamada, Hideki Katagiri, Yoshiyuki Hamamoto, Srikanth Deenadayalan, Andrea Navarria, Keiji Nishijima, Yutaka Seino. Lancet Diabetes Endocrinol 2020
25
50

A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.
Tine A Bækdal, Astrid Breitschaft, Andrea Navarria, Cilie W Hansen. Expert Opin Drug Metab Toxicol 2018
20
50

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
Vanita R Aroda, Julio Rosenstock, Yasuo Terauchi, Yuksel Altuntas, Nebojsa M Lalic, Enrique C Morales Villegas, Ole K Jeppesen, Erik Christiansen, Christin L Hertz, Martin Haluzík. Diabetes Care 2019
72
50

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
Helena W Rodbard, Julio Rosenstock, Luis H Canani, Chaicharn Deerochanawong, Janusz Gumprecht, Søren Østergaard Lindberg, Ildiko Lingvay, Anette Luther Søndergaard, Marianne Bach Treppendahl, Eduard Montanya. Diabetes Care 2019
71
50


Glucagon-like peptide 1 (GLP-1).
T D Müller, B Finan, S R Bloom, D D'Alessio, D J Drucker, P R Flatt, A Fritsche, F Gribble, H J Grill, J F Habener,[...]. Mol Metab 2019
163
50

Stimulation of incretin secreting cells.
Ramona Pais, Fiona M Gribble, Frank Reimann. Ther Adv Endocrinol Metab 2016
48
50

Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing.
Gopi Krishna Kolluru, Shyamal C Bir, Christopher G Kevil. Int J Vasc Med 2012
296
50

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.
Charlotte Granhall, Flemming L Søndergaard, Mette Thomsen, Thomas W Anderson. Clin Pharmacokinet 2018
38
50

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Julio Rosenstock, Dale Allison, Andreas L Birkenfeld, Thalia Marie Blicher, Srikanth Deenadayalan, Jacob Bonde Jacobsen, Pierre Serusclat, Rafael Violante, Hirotaka Watada, Melanie Davies. JAMA 2019
93
50

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
50

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Mansoor Husain, Andreas L Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G Eliaschewitz, Denise R Franco, Ole K Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D Pedersen,[...]. N Engl J Med 2019
327
50

Oral semaglutide in type 2 diabetes.
Sarah L Anderson, Trevor R Beutel, Jennifer M Trujillo. J Diabetes Complications 2020
8
50

Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.
Stephen T Buckley, Tine A Bækdal, Andreas Vegge, Stine J Maarbjerg, Charles Pyke, Jonas Ahnfelt-Rønne, Kim G Madsen, Susanne G Schéele, Tomas Alanentalo, Rikke K Kirk,[...]. Sci Transl Med 2018
104
50

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment.
Tine A Baekdal, Mette Thomsen, Viera Kupčová, Cilie W Hansen, Thomas W Anderson. J Clin Pharmacol 2018
28
50


GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.
Andrei C Sposito, Otávio Berwanger, Luiz Sérgio F de Carvalho, José Francisco Kerr Saraiva. Cardiovasc Diabetol 2018
44
50

The incretin system and its role in type 2 diabetes mellitus.
Jens Juul Holst, Tina Vilsbøll, Carolyn F Deacon. Mol Cell Endocrinol 2009
328
50

Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function.
Chinmay S Marathe, Christopher K Rayner, Karen L Jones, Michael Horowitz. Exp Diabetes Res 2011
53
50

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.
Charlotte Granhall, Morten Donsmark, Thalia M Blicher, Georg Golor, Flemming L Søndergaard, Mette Thomsen, Tine A Bækdal. Clin Pharmacokinet 2019
37
50

Effects of GLP-1 on appetite and weight.
Meera Shah, Adrian Vella. Rev Endocr Metab Disord 2014
69
50


Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Andrew J Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G Holst, Miriam P Annett, Vanita R Aroda. Diabetes Care 2018
150
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.